Quantinno Capital Management LP Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Quantinno Capital Management LP grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 24.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,251 shares of the biopharmaceutical company’s stock after buying an additional 9,590 shares during the quarter. Quantinno Capital Management LP’s holdings in Regeneron Pharmaceuticals were worth $37,281,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of REGN. Brighton Jones LLC grew its position in Regeneron Pharmaceuticals by 261.8% during the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after acquiring an additional 686 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $226,000. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $3,183,000. Gabelli Funds LLC boosted its stake in shares of Regeneron Pharmaceuticals by 3.0% during the second quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock valued at $978,000 after purchasing an additional 55 shares during the period. Finally, Sei Investments Co. grew its holdings in shares of Regeneron Pharmaceuticals by 18.8% in the second quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after purchasing an additional 5,120 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Results exceeded expectations: Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above the roughly $3.82 billion consensus estimate. Non-GAAP EPS was $14.29 versus expectations of approximately $10.16, helping drive renewed investor interest. Regeneron Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Key growth products performed well: Dupixent sales, recorded by partner Sanofi, rose 38% to a record $6.0 billion, while U.S. EYLEA HD sales increased 52% to a record $596 million. Libtayo sales also grew 30% to $489 million, demonstrating strength beyond the company’s legacy EYLEA franchise. Regeneron beats quarterly estimates on eczema drug strength, shares rise
• Positive Sentiment: Pipeline and strategic expansion: Management highlighted its broader development pipeline, while a collaboration with Telix Pharmaceuticals could expand Regeneron’s oncology presence through next-generation radiopharmaceutical therapies. Why Regeneron is up after mixed Q2 results and Telix oncology deal
• Neutral Sentiment: Dividend declared: Regeneron announced a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield provides limited income support but is unlikely to be a major valuation driver.
• Neutral Sentiment: Broader sector weakness: Healthcare stocks declined late in the session, creating a headwind for the group even as Regeneron benefited from its earnings release.
• Negative Sentiment: Fianlimab-Libtayo trial litigation: Multiple law firms publicized a securities class action alleging that Regeneron misrepresented the risks and protocol changes surrounding the failed Phase 3 melanoma trial. The allegations relate to investors who purchased shares from August 1, 2025, through May 15, 2026; the lead-plaintiff deadline is September 14, 2026. The lawsuit follows an earlier, severe market reaction to the trial failure and could add legal costs and reputational risk, although the claims have not been proven. Hagens Berman Regeneron securities class action alert

Regeneron Pharmaceuticals Price Performance

REGN opened at $738.34 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The stock has a market capitalization of $78.06 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 27.78 and a beta of 0.24. The stock’s 50 day moving average price is $640.66 and its 200-day moving average price is $711.35. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the firm posted $12.81 earnings per share. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 2.06 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on REGN shares. Piper Sandler decreased their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a research note on Thursday, July 9th. HSBC cut their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Barclays decreased their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $787.88.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.